3 High Dividend Dow Jones Stocks
Thanks to surging stock prices over the past two years,…
Sell
23
BOVNF Quote, Financials, Valuation and Earnings
Last price:
$4.70
Seasonality move
:
-10.76%
Day range:
$4.70 - $4.70
52-week range:
$4.70 - $4.70
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
84.18x
P/B ratio:
3.11x
Volume:
--
Avg. volume:
--
1-year change:
--
Market cap:
$309.3M
Revenue:
$6.7M
EPS (TTM):
-$0.59
Analysts' Opinion
-
Consensus RatingBioInvent International AB has received a consensus rating of --. The company's average rating is a -- based on 0 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target DownsideAccording to analysts' consensus price target of --, BioInvent International AB has an estimated downside of -- from its current price of $4.70.
-
Price Target UpsideAccording to analysts, the highest upside price target is -- representing -100% upside increase from its current price of $4.70.
Fair Value
-
According to the consensus of 0 analysts, BioInvent International AB has -- downside to fair value with a price target of -- per share.
BOVNF vs. S&P 500
-
Over the past 5 trading days, BioInvent International AB has underperformed the S&P 500 by -1.57% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
BioInvent International AB does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
BioInvent International AB revenues have been falling on a year-over-year basis for 4 quarters in a row. In the most recent quarter BioInvent International AB reported revenues of $1.2M.
Earnings Growth
-
BioInvent International AB has grown year-over-year earnings for 0 quarters straight. In the most recent quarter BioInvent International AB reported earnings per share of -$0.14.
Enterprise value:
215M
EV / Invested capital:
--
Price / LTM sales:
84.18x
EV / EBIT:
--
EV / Revenue:
58.47x
PEG ratio (5yr expected):
-0.25x
EV / Free cash flow:
-6.03x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
-31.35%
Net Income Margin (TTM):
-1057.9%
Return On Equity:
-33.69%
Return On Invested Capital:
-33.69%
Operating Margin:
-839.44%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $31.7M | $7.2M | $3.7M | $2.5M | $1.2M | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$5.9M | -$31.8M | -$43.4M | -$7.5M | -$10.3M | |
| EBITDA | -$4.4M | -$29.5M | -$37.7M | -$7.1M | -$9.9M | |
| Diluted EPS | -$0.08 | -$0.45 | -$0.59 | -$0.10 | -$0.14 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $75.2M | $145.5M | $114M | $112.6M | $100.3M | |
| Total Assets | $78.5M | $172.9M | $157.6M | $135.9M | $107.9M | |
| Current Liabilities | $5M | $5.9M | $4.8M | $5.8M | $7.5M | |
| Total Liabilities | $5.5M | $8.5M | $6.4M | $7M | $8.4M | |
| Total Equity | $72.9M | $164.4M | $151.2M | $128.8M | $99.5M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$6.1M | -$32M | -$34.5M | -$9.4M | -$9.8M | |
| Cash From Investing | -$81.2M | $15.9M | $47.5M | $11M | $34.6M | |
| Cash From Financing | $27M | $3.4M | -$749.5K | -$246.4K | -$211.9K | |
| Free Cash Flow | -$7.1M | -$33.6M | -$35.7M | -$9.7M | -$10M | |
BOVNF
Sector
Market Cap
$309.3M
$48.9M
Price % of 52-Week High
100%
49.34%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.74%
1-Year Price Total Return
--
-30.56%
Beta (5-Year)
0.697
0.754
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$4.70
200-day SMA
Sell
Level
$4.70
Bollinger Bands (100)
Sell
Level
4.7 - 4.7
Chaikin Money Flow
Sell
Level
-11.8K
20-day SMA
Sell
Level
$4.70
Relative Strength Index (RSI14)
Sell
Level
0.00
ADX Line
Buy
Level
61.09
Williams %R
Buy
Level
0
50-day SMA
Sell
Level
$4.70
MACD (12, 26)
Sell
Level
0.00
25-day Aroon Oscillator
Sell
Level
0
On Balance Volume
Sell
Level
-58.6K
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
Buy
CA Score
(Annual)
Level (0.6323)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (4)
Sell
Ohlson Score
Level (3.8409)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
Sell
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
BioInvent International AB is a clinical-stage biotech company. It discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently four drug candidates in five ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors, respectively. The company's validated, proprietary F.I.R.S.T technology platform identifies both targets and the antibodies that bind to them, generating many new drug candidates to fuel the company's own clinical development pipeline and providing licensing and partnering opportunities. The company's pipeline portfolio comprises BI-1206, an antagonistic blocking antibody for the treatment of non-Hodgkin’s lymphoma, and BI-1808 and BI-1910 (anti-TNFR2) for solid cancers.
Stock Forecast FAQ
In the current month, BOVNF has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The BOVNF average analyst price target in the past 3 months is --.
-
Where Will BioInvent International AB Stock Be In 1 Year?
According to analysts, the consensus estimate is that BioInvent International AB share price will drop to -- per share over the next 12 months.
-
What Do Analysts Say About BioInvent International AB?
Analysts are divided on their view about BioInvent International AB share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that BioInvent International AB is a Sell and believe this share price will rise from its current level to --.
-
What Is BioInvent International AB's Price Target?
The price target for BioInvent International AB over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is BOVNF A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for BioInvent International AB is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of BOVNF?
You can purchase shares of BioInvent International AB via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase BioInvent International AB shares.
-
What Is The BioInvent International AB Share Price Today?
BioInvent International AB was last trading at $4.70 per share. This represents the most recent stock quote for BioInvent International AB. Yesterday, BioInvent International AB closed at $4.70 per share.
-
How To Buy BioInvent International AB Stock Online?
In order to purchase BioInvent International AB stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will American Tower Stock Recover?
The performance of the real estate investment trust, or REIT,…
Will Booking Holdings Stock Split?
Booking Holdings, the travel and technology company that owns brands…
Stock Ideas
Sell
42
Is AAPL Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 40x
Buy
59
Is NVDA Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 125x
Sell
46
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 36x
Alerts
Sell
50
NARI alert for Jan 7
Inari Medical [NARI] is up 30.64% over the past day.
Buy
70
PDEX alert for Jan 7
Pro-Dex [PDEX] is up 22.41% over the past day.
Buy
52
ALCO alert for Jan 7
Alico [ALCO] is up 18.99% over the past day.
